Tessering Biosciences creates novel therapeutics for women's health by integrating structural biology, computational chemistry, and medicinal chemistry. Their drug development platform generates a pipeline of multi‑indication therapies aimed at extending healthspan and wellbeing across all stages of a woman's life, focusing on estrogen‑receptor biology and related targets.
Funding
Funding not disclosed
Founders
Product
Problem
Women’s health conditions, particularly those involving estrogen‑receptor pathways, remain under‑researched and lack targeted therapeutics, leading to gaps in treatment across reproductive, metabolic, and age‑related disorders.
Solution
Tessering Biosciences applies an integrated platform that combines structural biology, computational chemistry, and medicinal chemistry to design novel estrogen‑receptor modulators. By leveraging high‑resolution protein structures and in‑silico screening, the company accelerates the discovery of multi‑indication drug candidates aimed at extending healthspan and wellbeing for women at every life stage. The platform iterates rapidly from target validation to lead optimization, generating a pipeline of therapeutics that address both reproductive health and broader longevity‑related indications. Clinical translation is guided by a focus on safety, efficacy, and the specific hormonal contexts of female patients.
Target Audience
Primary customers are pharmaceutical partners, biotech firms, and research institutions seeking estrogen‑receptor‑focused therapeutics for women’s health, as well as clinical development teams pursuing multi‑indication drug programs.
Features
- Structure‑based drug design using crystallography and cryo‑EM to map estrogen‑receptor conformations
- AI‑driven computational chemistry workflows for virtual screening of large chemical libraries
- Medicinal chemistry optimization cycles that integrate pharmacokinetic and toxicity predictions
- Multi‑indication pipeline targeting reproductive, metabolic, and age‑related estrogen‑driven diseases
- Platform scalability that enables rapid progression from target identification to preclinical candidate selection